Hypertension and current issues in compliance and patient outcomes

Current Hypertension Reports

Volumn 2, Issue 6, 2000, Pages 510-514

  Zyczynski, Teresa M ^a   Coyne, Karin S ^b  

^a ASTRAZENECA   (United Kingdom)

^b UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE MONITORING; COST BENEFIT ANALYSIS; DOCTOR PATIENT RELATION; ECONOMICS; HUMAN; HYPERTENSION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; COST-BENEFIT ANALYSIS; HUMANS; HYPERTENSION; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PHYSICIAN-PATIENT RELATIONS; QUALITY OF LIFE;

EID: 0034545853     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-996-0034-7     Document Type: Article

References (29)

1. Burt VL, Cutler JA, Higgins M, et al.: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the Health Examination Surveys, 1960 to 1991. Hypertension 1995, 26: 60-69.
2. American Heart Association. http://www.americanheart.org. July 20, 2000.
3. Ebrahim S: Detection, adherence and control of hypertension for the prevention of stroke: a systematic review. Health Technol Assessment 1998, 2: 20-28.
4. Dusing R, Weisser B, Mengden T, et al.: Changes in antihypertensive therapy - the role of adverse effects and adherence. Blood Press 1998, 7: 313-315.
5. Kjellgren KI, Svesson S, Ahlner J, et al.: Antihypertensive medication in clinical encounters. Int J Cardiol 1998, 64: 161-169.
6. Hill MN, Bone LR, Kim MT, et al.: Barriers to hypertension care and control in young urban black men. Am J Hypertens. 1999, 12: 951-958.
7. Vaur L, Vaisse B, Genes N, et al.: Use of electronic pill boxes to assess risk of poor treatment adherence. Am J Hypertens. 1999, 12: 374-380.
8. Andrejak M, Genes N, Vaur L, et al.: Electronic pill-boxes in the evaluation of antihypertensive treatment adherence: comparison of once daily versus twice daily regimen. Am J Hypertens. 2000, 13: 184-190.
9. Mounier-Vehier C, Bernaud C, Carré A, et al.: Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release. Am J Hypertens 1998, 11: 478-486.
10. Waeber B, Burnier M, Brunner HR: Compliance with antihypertensive therapy. Clin Exp Hypertens 1999, 21: 973-985.
11. Waeber B, Vetter W, Darioli R, et al.: Improved blood pressure control by monitoring adherence with antihypertensive therapy. Int J Clin Pract 1999, 53: 37-38.
12. Ashida T, Sugiyam T, Okuno S, et al.: Relationship between blood pressure measurement and medication adherence and name recognition of antihypertensive drugs. Hypertens Res 2000, 23: 21-24.
13. Ward HJ, Morisky DE, Lees NB, et al.: A clinic and communitybased approach to hypertension control for an underserved minority population: design and methods. Am J Hypertens 2000, 13: 177-183.
14. Dahlof B, Lindholm LH, Carney S, et al.: Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. J Hypertens 1997, 15: 1327-1335.
15. Karlberg BE, Lins LE, Hermansson K: Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens 1999, 17: 293-302.
16. Grimm RH, Grandits GA, Cutler JA, et al.: Relationship of quality-of-life measures to long-term lifestyle and drug treatment in the treatment of mild hypertension study. Arch Intern Med 1997, 157: 638-648.
17. Croog SH, Levine S, Testa MA, et al.: The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986, 314: 1657-1664.
18. Ware JE, Snow KK, Kosinski M, et al.: SF-36 Health Survey Manual & Interpretation Guide. Boston: Nimrod Press; 1993.
19. Fletcher AE, Bulpitt CJ, Chase DM, et al.: Quality of life with three antihypertensive treatments. Cilazapril, Atenolol, Nifedipine. Hypertension 1992, 19: 499-507.
20. Breed JGS, Ciampricotti R, Tromp GP: Quality of life perception during antihypertensive treatment: a comparative study of bisoprolol and enalapril. J Cardiovasc Pharmacol 1992, 20: 750-755.
21. Yodfat Y, Bar-On D, Amir M, et al.: Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study. J Hum Hypertens 1996, 10: 117-122.
22. Battersby C, Hartley K, Fletcher AE, et al.: Quality of life in treated hypertension: a case-control community based study. J Hum Hypertens 1995, 9: 981-986.
23. Hjemdahl P, Wiklund IK: Quality of life on antihypertensive drug therapy: scientific end-point or marketing exercise? J Hypertens 1992, 10: 1437-1446.
24. Muller A, Montoya P, Schandry R, et al.: Changes in physical symptoms, blood pressure and quality of life over 30 days. Behav Res Ther 1994, 32: 593-603.
25. Kullman S, Svardsudd K: Differences in perceived symptoms/ quality of life in untreated hypertensive and normotensive men. Scand J Prim Health Care 1990, Suppl 1: 47-53.
26. Wiklund I, Halling K, Ryden-Bergsten T, et al.: Does lowering the blood pressure improve the mood? Quality of life results from the Hypertension Optimal Treatment (HOT) study. Blood Press 1997, 6: 357-364.
27. Caro JJ, Speckman JL, Salas M, et al.: Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. Can J Med Assoc 1999, 160: 41-46.
28. Weir MR, Maibach EW, Bakris GL, et al.: Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med 2000, 160: 481-490.
29. Schwartz LM, Woloshin S: Changing disease definitions: implications for disease prevalence. Analysis of the third National Health and Nutrition Examination Survey, 1988-1994. Eff Clin Pract 1999, 2: 76-85.